Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer - NICE guidance now available

Published: 7 February 2018
Breast cancer
Breast cancer is the most common cancer in women

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service (NHS) on the use of the drug fulvestrant (Faslodex®) informed by a report produced by SHTAC.

NICE’s guidance does not recommend fulvestrant for treating locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.  However, NICE’s recommendation is not intended to affect treatment with fulvestrant that was started in the NHS before this guidance was published.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.

 

Privacy Settings